In vitro studies3-5 provide support for our findings identifying the IRSP as an underlying mechanism by which combination of insulin with non-insulin T2D medications may modulate AD neuropathology even in the absence of comorbid T2D. Here, INS is linked to type 2 diabetes mellitus.